Barclays raised the firm’s price target on Exelixis (EXEL) to $40 from $29 and keeps an Equal Weight rating on the shares. The firm updated the company’s model to reflect a higher probability of sucess in colorectal cancer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Pan-Tumor Rollover Study: A New Horizon in Cancer Treatment
- RBC downgrades Exelixis on valuation ahead of Cabometyx cliff
- Exelixis downgraded to Sector Perform from Outperform at RBC Capital
- Truist biotech analyst holds an analyst/industry conference call
- Exelixis price target raised to $53 from $47 at H.C. Wainwright